Advertisement

Topics

Durvalumab Falls Short in Head and Neck Cancer

16:05 EST 7 Dec 2018 | OncLive

Durvalumab alone and in combination with tremelimumab did not improve overall survival versus standard-of-care chemotherapy in patients with recurrent or metastatic head and neck squamous cell carcinoma who progressed after platinum-based chemotherapy.

Original Article: Durvalumab Falls Short in Head and Neck Cancer

NEXT ARTICLE

More From BioPortfolio on "Durvalumab Falls Short in Head and Neck Cancer"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Skin cancers
There are three main types of skin cancer: basal cell carcinoma, squamous cell carcinoma and malignant melanoma. Basal cell carcinoma Basal cell carcinoma, or BCC, is a cancer of the basal cells at the bottom of the epidermis. It’s very common ...